Zacks Small Cap Has Positive Outlook of MIRA FY2026 Earnings

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Equities researchers at Zacks Small Cap lifted their FY2026 earnings per share estimates for shares of MIRA Pharmaceuticals in a report issued on Tuesday, April 1st. Zacks Small Cap analyst B. Sorensen now expects that the company will earn ($0.53) per share for the year, up from their prior estimate of ($0.54). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.14.

MIRA Pharmaceuticals Trading Down 7.3 %

MIRA Pharmaceuticals stock opened at $0.83 on Thursday. MIRA Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $5.01. The firm has a market capitalization of $14.03 million, a PE ratio of -1.49 and a beta of 2.05. The firm’s 50 day simple moving average is $1.10 and its 200 day simple moving average is $1.21.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at about $112,000. Virtu Financial LLC bought a new stake in MIRA Pharmaceuticals during the fourth quarter valued at approximately $72,000. Renaissance Technologies LLC bought a new position in shares of MIRA Pharmaceuticals in the 4th quarter worth $52,000. Northern Trust Corp raised its position in shares of MIRA Pharmaceuticals by 50.9% during the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after buying an additional 10,238 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of MIRA Pharmaceuticals during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.